C-Ring Women’s Leadership Award nominations open
Prestigous award honors academically successful undergraduate women who exemplify advocacy for women and girls and a commitment to UC and community
The University of Cincinnati Women’s Center is accepting nominations for the 2020 C-Ring Women’s Leadership Award now through Oct. 11.
The award – a 10-karat gold ring – represents a legacy of UC undergraduate women who exemplify advocacy for women and girls, a commitment to the university and the community and academic excellence.
To be eligible for the award, the student must graduate between August 2019 and May 2020 with a 3.2 GPA and demonstrate a record of advocacy on behalf of women and girls.
The UC Women’s Center will celebrate all nominated women and their nominators at an October reception. Finalists and their nominators will be recognized at the annual UC Women’s Center Award Ceremony on March 27.
Faculty, staff and students may submit nominations via CampusLINK by Oct. 11. Students do not have to be nominated to apply. Applications must be submitted via CampusLINK by Nov. 25.
Questions may be directed to Assistant Vice President for Student Affairs Nicole Mayo.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Free GED prep classes offered at UC Clermont
December 11, 2025
UC Aspire is launching a free 16-week GED Prep Program at the University of Cincinnati Clermont College starting the week of Jan. 26.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.